Satysfakcja i preferencje pacjentów dotyczące leczenia lanreotydem Autogel w akromegalii

Witek, Przemysław; Mucha, S; Ruchała, Marek

doi:10.5603/ep.2016.0066

Cited by 14 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment satisfaction in our study was high, as evidenced by the mean global satisfaction score (75.1) on the TSQM-9 scale. These findings are consistent with previous reports demonstrating good patient satisfaction with lanreotide autogel [11,29,30]. Treatment adherence rates were excellent (94.5%), with only 6 of the 109 patients missing more than one injection.…”

Section: Treatment Satisfaction and Adherencesupporting

confidence: 92%

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

et al. 2020

View full text Add to dashboard Cite

Purpose Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and wellreceived among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs). We further evaluated the effectiveness of lanreotide autogel 120 mg delivered at EDIs (>4 weeks) in routine clinical practice. Methods Cross-sectional, multicentre, observational study conducted to determine the effectiveness-measured by control of serum insulin-like growth factor 1 (IGF-1)-of lanreotide autogel 120 mg at dosing intervals >4 weeks for ≥6 months in selected patients with acromegaly treated in routine clinical practice (NCT02807233). Secondary assessments included control of growth hormone (GH) levels, treatment adherence, patient satisfaction, and quality of life (QoL) using validated questionnaires (EQ-5D, AcroQoL, and TSQM-9). Patients who received radiotherapy within the last 6 months were excluded. Results Among 109 patients evaluated, mean (SD) age was 59.1 (13.2) years. IGF-1 values were normal (mean [SD]: 175.0 [74.5], 95% CI: 160.8-189.1) in 91.7% of cases and normal in 91.4% of patients without previous radiotherapy treatment (n = 81). GH levels were ≤2.5 and ≤1 ng/mL, respectively, in 80.6% and 58.3%. Most patients were treated either every 5-6 (57.8%) or 7-8 weeks (38.5%), with 2.8% treated greater than every 8 weeks. The mean AcroQoL score was 63.0 (20.1). The mean global treatment satisfaction score (TSQM-9) was 75.1 (16.6). Treatment adherence (defined as no missed injections) was 94.5%. Conclusion Lanreotide autogel 120 mg at intervals of >4 weeks provided IGF-1 control in more than 90% of patients with acromegaly. Treatment satisfaction and adherence were good. These findings support use of extended dosing intervals in patients who have achieved good biochemical control with long-acting SSAs.

show abstract

Section: Treatment Satisfaction and Adherencesupporting

confidence: 92%

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Patients with active acromegaly, after unsuccessful surgery for pituitary adenoma or awaiting the effects of adjuvant radiotherapy, should receive long-acting somatostatin analogues at doses that ensure normalisation of the GH and IGF-1 levels [3,5,17]. The option of using lanreotide autogel 120 mg less than once a month (even every 56 days) significantly reduces treatment costs and at the same time increases the patient's comfort and quality of life [11,22,25,26].…”

Section: Continue Therapy Control Development Of Disease Complicationsmentioning

confidence: 99%

“…Pacjenci z czynną akromegalią, po nieskutecznej operacji gruczolaka przysadki lub w oczekiwaniu na efekty radioterapii, jako leczenie uzupełniające winni stale przyjmować analogi somatostatyny o przedłużonym działaniu w dawkach normalizujących stężenia GH i IGF-1 [3,5,17]. Możliwość zastosowania lanreotydu Autogel 120 mg rzadziej niż co miesiąc (nawet co 56 dni) istotnie obniża koszty terapii oraz zwiększa komfort i jakość życia chorego [11,22,25,26].…”

Section: Wytyczneunclassified

Diagnostics and treatment of acromegaly — updated recommendations of the Polish Society of Endocrinology

Bolanowski

Ruchała

Zgliczyński

et al. 2019

Endokrynologia Polska

Self Cite

View full text Add to dashboard Cite

Acromegaly is a rare disease caused by excessive production of growth hormone (GH), typically by a pituitary tumour. The diagnosis is usually delayed, and patients frequently develop various complications that cause premature mortality. In patients with hypertension, heart failure, diabetes, and arthropathies that are not age-specific, attention should be paid to signs of acromegaly. Insulin-like growth factor 1 (IGF-1) assay should be used as a screening test whenever acromegaly is suspected. Further diagnostic investigations and treatment should be carried out at specialist centres. First-line treatment involves selective excision of pituitary adenoma using transsphenoidal access. Patients with chances of cure with surgical removal of the pituitary tumour should be referred to centres that have experience in this type of procedure, following pharmacological preparation. Other patients, as well as patients after failed neurosurgical treatment, should first receive chronic treatment with first-generation somatostatin analogues. For second-line treatment, pasireotide, pegvisomant, cabergoline, or combinations thereof should be considered. In every case, acromegaly sequelae require life-long monitoring and active treatment. Current recommendations, being an updated version of the recommendations published in Endokrynologia Polska in 2014, which take into account the Polish situation, should prove useful in the management of patients with acromegaly. (Endokrynol Pol 2019; 70 (1): 2-10)

show abstract

“…PROs are increasingly recognized as important metrics for evaluating treatment effectiveness (symptomatic control), as well as treatment side effects and convenience [13, 17, 18]. Evaluation of HRQoL can highlight the patient’s viewpoint of clinical aspects not always discussed at the visits with providers, but is of significant importance for the patient’s daily life.…”

Section: Discussionmentioning

confidence: 99%

Development of a novel patient-reported measure for acromegaly: the Acro-TSQ

et al. 2019

View full text Add to dashboard Cite

PurposeSomatostatin analogs (SSAs) represent a mainstay of medical treatment for acromegaly, currently available as either intramuscular or deep subcutaneous injections. Patient-reported outcomes (PROs) are increasingly common as relevant outcomes in studies of acromegaly and its treatment, but there are no validated PRO measures available that focus on the disease burden and the impact of treatment, specifically designed for use in patients with acromegaly. We sought to develop a new and unique PRO measure, the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ).MethodsConcept elicitation (CE) interviews were conducted with acromegaly patients in the United States receiving SSA injections at a stable dose for ≥ 6 months. A questionnaire was drafted based on these interviews; combined CE and cognitive debriefing (CE/CD) interviews were then conducted to confirm the content, clarity, and relevance of the questionnaire.ResultsNineteen subjects completed interviews [n = 9 CE, n = 10 CE/CD; n = 15 Lanreotide Depot/Autogel (Somatuline), n = 4 Octreotide LAR (Sandostatin LAR)]. Most subjects responded positively when asked about the effectiveness of their current treatment; however, breakthrough symptoms, injection site reactions, and side effects were commonly reported and had negative impacts on social and emotional well-being and daily activities. All 10 subjects involved in debriefing interviews found the questionnaire to be relevant, easy to complete, and found the response options to be clear. The resulting 26-item Acro-TSQ covers symptoms and symptom control, gastrointestinal side effects and their impact on daily activities, the emotional impact of treatment, convenience and ease of use, and overall satisfaction.ConclusionsThe Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment.

show abstract

Satysfakcja i preferencje pacjentów dotyczące leczenia lanreotydem Autogel w akromegalii

Cited by 14 publications

References 19 publications

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

Diagnostics and treatment of acromegaly — updated recommendations of the Polish Society of Endocrinology

Development of a novel patient-reported measure for acromegaly: the Acro-TSQ

Contact Info

Product

Resources

About